Precigen (FRA:I5X) Total Liabilities : €34.80 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Precigen Total Liabilities?

Precigen's Total Liabilities for the quarter that ended in Mar. 2024 was €34.80 Mil.

Precigen's quarterly Total Liabilities declined from Sep. 2023 (€40.30 Mil) to Dec. 2023 (€29.84 Mil) but then increased from Dec. 2023 (€29.84 Mil) to Mar. 2024 (€34.80 Mil).

Precigen's annual Total Liabilities declined from Dec. 2021 (€223.47 Mil) to Dec. 2022 (€84.69 Mil) and declined from Dec. 2022 (€84.69 Mil) to Dec. 2023 (€29.84 Mil).

Precigen Total Liabilities Historical Data

The historical data trend for Precigen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Total Liabilities Chart

Precigen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

345.65

203.37

223.47

84.69

29.84

Precigen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															53.62	38.14	40.30	29.84	34.80

Precigen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Precigen's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	21.077	+	(5.406	+	-4.4408920985006E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	3.361	+	0)
	=	29.84

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	138.506	-	108.663
	=	29.84

Precigen's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26.472	+	(4.956	+	-2.2204460492503E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	3.374	+	0)
	=	34.80

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	124.059	-	89.257
	=	34.80

Precigen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Precigen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Precigen (FRA:I5X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (FRA:I5X) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PGEN:USA I5X:Germany

Address

20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876

Website

http://www.precigen.com

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen (FRA:I5X) Headlines

No Headlines